Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MT-303 |
| Synonyms | |
| Therapy Description |
MT-303 comprises a lipid nanoparticle-encapsulated mRNA encoding a chimeric antigen receptor (CAR) targeting GPC3 linked to a truncated form of CD89, which potentially enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MT-303 | MT 303|MT303 | GPC3 Immune Cell Therapy 8 | MT-303 comprises a lipid nanoparticle-encapsulated mRNA encoding a chimeric antigen receptor (CAR) targeting GPC3 linked to a truncated form of CD89, which potentially enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06478693 | Phase I | MT-303 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | Recruiting | AUS | 1 |